Sign In
Buy ALZN
$1.31
-0.0400 (-2.96%)
At Close: Jul 31, 2026
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital
ATLANTA, March 11, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of A
ATLANTA, March 04, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of A
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
08:00am, Tuesday, 25'th Feb 2025
ATLANTA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Al
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
10:41am, Thursday, 23'rd Jan 2025
Here is how Alzamend Neuro, Inc. (ALZN) and Beam Therapeutics Inc. (BEAM) have performed compared to their sector so far this year.
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
09:41am, Monday, 19'th Aug 2024
Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
08:00am, Tuesday, 07'th May 2024
ATLANTA--(BUSINESS WIRE)---- $ALZN #10_day_termination_process_started--Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program.
PRISM MarketView – Weekly Market Report – April 26, 2024
02:39pm, Friday, 26'th Apr 2024
PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 – PRISM MarketView – Equities were higher through th
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement
08:00am, Thursday, 16'th Nov 2023
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.
Alzamend Neuro Announces Reverse Stock Split
08:00am, Monday, 30'th Oct 2023
ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
08:00am, Wednesday, 24'th May 2023
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
12:38pm, Thursday, 11'th May 2023
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
LAS VEGAS--(BUSINESS WIRE)--Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance” or the “Company”), is proud to announce that Alzamend Neuro, Inc. (Nasdaq:
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’
